Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Change in Account Payables: 2022-2024

Historic Change in Account Payables for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to $1,211.5 billion.

  • Addex Therapeutics' Change in Account Payables fell 14.16% to $1,211.5 billion in Q4 2024 from the same period last year, while for Dec 2024 it was -$13.5 billion, marking a year-over-year decrease of 353.22%. This contributed to the annual value of -$1.3 million for FY2024, which is 90.80% down from last year.
  • Latest data reveals that Addex Therapeutics reported Change in Account Payables of $1,211.5 billion as of Q4 2024, which was up 198.90% from -$1,224.9 billion recorded in Q3 2024.
  • In the past 5 years, Addex Therapeutics' Change in Account Payables registered a high of $1,411.3 billion during Q4 2023, and its lowest value of -$1,224.9 billion during Q3 2024.
  • Moreover, its 3-year median value for Change in Account Payables was -$126,636 (2022), whereas its average is -$679.0 million.
  • Within the past 5 years, the most significant YoY rise in Addex Therapeutics' Change in Account Payables was 171,865,443.79% (2023), while the steepest drop was 246,610,809.04% (2023).
  • Over the past 3 years, Addex Therapeutics' Change in Account Payables (Quarterly) stood at -$821,184 in 2022, then skyrocketed by 171,865,443.79% to $1,411.3 billion in 2023, then fell by 14.16% to $1,211.5 billion in 2024.
  • Its Change in Account Payables was $1,211.5 billion in Q4 2024, compared to -$1,224.9 billion in Q3 2024 and -$1.7 million in Q2 2024.